Search hospitals

>

Louisiana

>

New Orleans

Ochsner Medical Center Jefferson

Claim this profile

New Orleans, Louisiana 70121

Global Leader in Cancer

Global Leader in Breast Cancer

Conducts research for Lung Cancer

Conducts research for Brain Tumor

Conducts research for Lymphoma

575 reported clinical trials

69 medical researchers

Photo of Ochsner Medical Center Jefferson in New OrleansPhoto of Ochsner Medical Center Jefferson in New OrleansPhoto of Ochsner Medical Center Jefferson in New Orleans

Summary

Ochsner Medical Center Jefferson is a medical facility located in New Orleans, Louisiana. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Brain Tumor, Lymphoma and other specialties. Ochsner Medical Center Jefferson is involved with conducting 575 clinical trials across 996 conditions. There are 69 research doctors associated with this hospital, such as Craig Lotterman, Marc Matrana, MD, Jonathan Mizrahi, MD, and John Cole, MD.

Area of expertise

1

Cancer

Global Leader

Ochsner Medical Center Jefferson has run 84 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage I
Stage II
2

Breast Cancer

Global Leader

Ochsner Medical Center Jefferson has run 80 trials for Breast Cancer. Some of their research focus areas include:

HER2 negative
ER positive
Stage IV

Top PIs

Clinical Trials running at Ochsner Medical Center Jefferson

Cancer

Breast Cancer

Ovarian Cancer

Pancreatic Cancer

Breast cancer

Prostate Cancer

Bladder Cancer

Lung Cancer

Non-Small Cell Lung Cancer

Testicular cancer

Image of trial facility.

Text-Based Smoking Cessation Program

for Rural Cancer Survivors

This phase III trial compares the effect of text-based cessation intervention to a manual in helping rural cancer patients who smoke, quit. Text-based scheduled gradual reduction may reduce the frequency of cigarette use to zero and may be effective in quitting smoking.

Recruiting

2 awards

Phase 3

Image of trial facility.

Triptorelin

for Cancer

This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with an alkylating agents. Alkylating agents are part of standard chemotherapy, but may cause damage to the ovaries. If the ovaries are not working well or completely shut down, then it will be difficult or impossible to get pregnant in the future. Triptorelin works by blocking certain hormones and causing the ovaries to slow down or pause normal activity. The triptorelin used in this study stays active in the body for 24 weeks or about 6 months after a dose is given. After triptorelin is cleared from the body, the ovaries resume normal activities. Adding triptorelin before the start of chemotherapy treatment may reduce the chances of damage to the ovaries.

Recruiting

2 awards

Phase 3

4 criteria

Image of trial facility.

Chemotherapy

for Cancer

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Chemotherapy drugs, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.

Recruiting

2 awards

Phase 3

26 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Ochsner Medical Center Jefferson?

Where is Ochsner Medical Center Jefferson located?

Who should I call to ask about financial aid or insurance network?

What insurance does Ochsner Medical Center Jefferson accept?

What awards or recognition has Ochsner Medical Center Jefferson received?